



February 7, 2022
NWMI-LTR-2021-011

U.S. Nuclear Regulatory Commission
ATTN: Document Control Desk
11555 Rockville Pike
Washington, DC 20555

Mr. Michael Balazik
Research and Test Reactors Branch A
Division of Policy and Rulemaking
Office of Nuclear Reactor Regulation

RE: Request for Termination of Northwest Medical Isotopes, LLC (NWMI) Construction Permit No. CPMIF-002 (Docket No. 50-609)

Reference:

1. Construction Permit No. CPMIF-002, Northwest Medical Isotopes, LLC, Docket No. 50-609 Medical Radioisotope Production Facility Construction Permit, Docket No. 50-609, dated May 9, 2018.
2. Geotechnical Exploration Report, Northwest Medical Isotopes, LLC, letter to USNRC dated May 9, 2019.

Dear Mr. Balazik:

Northwest Medical Isotopes, LLC ("NWMI") requests termination of License CPMIF-002 for the Radioisotope Production Facility, issued May 9, 2018, under 10 CFR 50.

The facility as described in Construction Permit Condition 3 has not been constructed; therefore, no physical or principal activities authorized by the Construction Permit, other than a geotechnical survey, have been conducted at the facility site located at Lot 15, Discovery Ridge, Columbia, Missouri. The geotechnical survey, required of Construction Permit Condition 3.G, consisted of borings used to determine the local soil stratigraphy. No other work was conducted on the site. The decision has been made that the facility will not be constructed, and therefore the Construction Permit should be terminated.

This land was and continues to be owned by the University of Missouri. It never changed ownership. The land remains undeveloped. Therefore, there are no decommissioning obligations associated with CPMIF-002 for this property.

No licensed radioactive material was received under Construction Permit CPMIF-002, and therefore there is no licensed material requiring disposition. Further, as the NWMI Radioisotope Production Facility was not constructed, and no licensed material was possessed or generated under the license; no licensed material was processed, used or stored in this area. Consistent with the MARSSIM approach (NUREG-1575, Supplement 1, Section 2.2, dated January 2009), this area is concluded to be non-impacted, and there is no reasonable potential for residual licensed radioactivity requiring decommissioning that would preclude termination of the license.

YGOI
NRR


Mr. Michael Balazik

Page 2

Of further note, I took over responsibilities from Dr. Larry Mullins as the Executive Chairman and Member of the Board of Managers of Northwest Medical Isotopes LLC in October 2021.

I solemnly declare and affirm that the foregoing information is true and correct under the penalty of perjury. Executed on February 7, 2022.

Sincerely,

DocuSigned by:

0FCAC0844A764CD...
Marty Cahill

NWMI Chief Executive Officer